

Accruing BMT CTN Studies

BMT CTN Protocol #	Protocol Title	Activation Date	Total # of Patients Accrued (Target)	Anticipated Closure Date
ECOG-ACRIN EA4151/BMT CTN 1601	A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission	8/29/2017	549 (689)	February 2024
BMT CTN 1705	A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 – Antitrypsin (AAT) Combined with Corticosteroids vs. Corticosteroids Alone for the Treatment of High-Risk Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant	1/9/2020	110 (136)	July 2023
SWOG S1803/BMT CTN 1706	Phase III Study of Daratumumab (NSC- 791647) + Lenalidomide (LD) or Lenalidomide (L) as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration	6/27/2019	926 (1100)	July 2023
BMT CTN 1902	Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomide	12/23/22	8 (40)	December 2023
BMT CTN 1903	Administration of HIV-specific T cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue - Auto-RESIST	10/26/21	4 (12)	July 2025
BMT CTN 1904	Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases	11/16/21	10 (40)	March 2025
ITN077A1/BMT CTN 1905	Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)	12/17/2019	34 (156)	December 2025
BMT CTN 2001	A Multi-Center, Phase 2 Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease	7/13/22	5 (29)	June 2024
PTCTC NMD2201/BMT CTN 2202	Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia (TransIT)	1/5/23	1 (234)	December 2026

Upcoming BMT CTN Studies

BMT CTN Protocol #	Protocol Title	Anticipated Activation Date
BMT CTN 2203	A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation	September 2023
ECOG-ACRIN EA4211/ BMT CTN 2204	A Randomized Phase III Trial of chemotherapy vs. pembrolizumab plus chemotherapy for relapsed/refractory classical Hodgkin Lymphoma	June 2023